sharon sanders
Editor-in-Chief & President
hat tip Senior Moderator Kent Nickell via email -
In response to events surrounding the novel influenza A (H1N1) outbreak, we would like to provide you with the following information. Please share this information with other interested parties.
If you have any questions on these or other clinical issues, please write to us at coca@cdc.gov.
Clinical Reminder - Antiviral Guidance
CDC recommends that antiviral treatment for novel influenza A (H1N1) be given as soon as possible after onset of symptoms for all hospitalized patients with confirmed, probable or suspected novel influenza (H1N1) and patients who are at higher risk for seasonal influenza complications. All hospitalized patients with novel influenza A (H1N1) infection should be monitored carefully and treated with antiviral therapy, including patients who seek care >48 hours after illness onset .
A recent study published in MMWR described diagnosis, medical conditions and treatment of 30 hospitalized patients in California with novel influenza A (H1N1) infection. The report indicated that 50% of 30 hospitalized patients received antiviral treatment with oseltamivir, and treatment was initiated within 48 hours of symptom onset in only 5 (16.6%) patients.
Among hospitalized patients with novel influenza A (H1N1), about half who have had chest x-rays done have findings consistent with pneumonia. Primary influenza virus pneumonia, with or without bacterial coinfection, is a potentially life-threatening illness. Empiric use of influenza antiviral medicines should be initiated as soon as possible for maximum benefit.
If bacterial coinfection is suspected, antibacterials directed at likely pathogens such as S. aureus and S. pneumoniae should also be initiated after appropriate bacteria cultures are taken.
Antiviral Treatment for Novel (H1N1) Influenza http://www.cdc.gov/h1n1flu/recommendations.htm
MMWR: Hospitalized Patients with Novel Influenza A (H1N1) Virus Infection --- May 18, 2009 / 58(Early Release);1-5 California, April--May, 2009 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58e0518a1.htm
In response to events surrounding the novel influenza A (H1N1) outbreak, we would like to provide you with the following information. Please share this information with other interested parties.
If you have any questions on these or other clinical issues, please write to us at coca@cdc.gov.
Clinical Reminder - Antiviral Guidance
CDC recommends that antiviral treatment for novel influenza A (H1N1) be given as soon as possible after onset of symptoms for all hospitalized patients with confirmed, probable or suspected novel influenza (H1N1) and patients who are at higher risk for seasonal influenza complications. All hospitalized patients with novel influenza A (H1N1) infection should be monitored carefully and treated with antiviral therapy, including patients who seek care >48 hours after illness onset .
A recent study published in MMWR described diagnosis, medical conditions and treatment of 30 hospitalized patients in California with novel influenza A (H1N1) infection. The report indicated that 50% of 30 hospitalized patients received antiviral treatment with oseltamivir, and treatment was initiated within 48 hours of symptom onset in only 5 (16.6%) patients.
Among hospitalized patients with novel influenza A (H1N1), about half who have had chest x-rays done have findings consistent with pneumonia. Primary influenza virus pneumonia, with or without bacterial coinfection, is a potentially life-threatening illness. Empiric use of influenza antiviral medicines should be initiated as soon as possible for maximum benefit.
If bacterial coinfection is suspected, antibacterials directed at likely pathogens such as S. aureus and S. pneumoniae should also be initiated after appropriate bacteria cultures are taken.
Antiviral Treatment for Novel (H1N1) Influenza http://www.cdc.gov/h1n1flu/recommendations.htm
MMWR: Hospitalized Patients with Novel Influenza A (H1N1) Virus Infection --- May 18, 2009 / 58(Early Release);1-5 California, April--May, 2009 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58e0518a1.htm